In the latest session, Beam Therapeutics Inc (NASDAQ: BEAM) closed at $28.20 down -2.86% from its previous closing price of $29.03. In other words, the price has decreased by -$0.83 from its previous closing price. On the day, 1505894 shares were traded.
Ratios:
For a deeper understanding of Beam Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.89 and its Current Ratio is at 5.89. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Upgraded its rating to Overweight and sets its target price to $40 from $38 previously.
On December 15, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $35.
Jefferies Downgraded its Buy to Hold on December 08, 2023, whereas the target price for the stock was revised from $75 to $30.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 02 ’24 when Simon Amy sold 16,530 shares for $30.54 per share. The transaction valued at 504,851 led to the insider holds 70,060 shares of the business.
Evans John M. sold 18,102 shares of BEAM for $581,617 on Apr 01 ’24. The CEO now owns 1,058,343 shares after completing the transaction at $32.13 per share. On Apr 01 ’24, another insider, Simon Amy, who serves as the Chief Medical Officer of the company, sold 7,157 shares for $32.13 each. As a result, the insider received 229,954 and left with 86,590 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BEAM now has a Market Capitalization of 2.30B and an Enterprise Value of 1.28B. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.10 while its Price-to-Book (P/B) ratio in mrq is 2.35. Its current Enterprise Value per Revenue stands at 3.39 whereas that against EBITDA is -8.19.
Stock Price History:
Over the past 52 weeks, BEAM has reached a high of $49.50, while it has fallen to a 52-week low of $16.95. The 50-Day Moving Average of the stock is 32.80, while the 200-Day Moving Average is calculated to be 27.81.
Shares Statistics:
For the past three months, BEAM has traded an average of 1.40M shares per day and 1.03M over the past ten days. A total of 81.63M shares are outstanding, with a floating share count of 67.88M. Insiders hold about 16.78% of the company’s shares, while institutions hold 76.98% stake in the company. Shares short for BEAM as of Mar 15, 2024 were 14.32M with a Short Ratio of 10.22, compared to 13.43M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 17.54% and a Short% of Float of 22.23%.
Earnings Estimates
There are 12 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$1.42 for the current quarter, with a high estimate of -$1.18 and a low estimate of -$2.16, while EPS last year was -$1.33. The consensus estimate for the next quarter is -$1.38, with high estimates of -$1.18 and low estimates of -$2.19.
Analysts are recommending an EPS of between -$4.51 and -$8.85 for the fiscal current year, implying an average EPS of -$5.38. EPS for the following year is -$5.07, with 13 analysts recommending between -$3.47 and -$5.85.
